Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Acquisitions & Divestments (2024 - 2025)

Immunome (IMNM) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $125.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Acquisitions & Divestments rose 316.67% year-over-year to $125.0 million, compared with a TTM value of $200.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $200.0 million, up 29.03% over the prior year.
  • Change in Acquisitions & Divestments was $125.0 million for Q3 2025 at Immunome, up from $60.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $125.0 million in Q3 2025 and bottomed at $15.0 million in Q1 2025.